Welcome to our dedicated page for Beam Therapeutics news (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics stock.
Beam Therapeutics Inc. (Nasdaq: BEAM) generates frequent news as a biotechnology company developing precision genetic medicines through base editing. News about BEAM stock often centers on clinical data readouts, regulatory designations and strategic updates across its hematology and liver-targeted genetic disease franchises.
Investors following BEAM news can expect detailed updates on risto-cel (formerly BEAM-101), an investigational ex vivo base editing cell therapy for sickle cell disease with severe vaso-occlusive crises. The company regularly reports safety and efficacy data from the BEACON Phase 1/2 trial, including measures such as fetal hemoglobin induction, reductions in sickle hemoglobin, engraftment times and markers of hemolysis, as well as designations like RMAT and orphan drug status from the U.S. Food and Drug Administration.
Another major source of headlines is BEAM-302, Beam’s liver-targeting program for alpha-1 antitrypsin deficiency (AATD). Company press releases describe Phase 1/2 trial progress, dose exploration, evidence of in vivo genetic correction of a disease-causing mutation, restoration of functional alpha-1 antitrypsin and regulatory interactions, including RMAT designation, orphan drug designation and participation in the FDA’s CDRP program.
Additional BEAM news items highlight developments in BEAM-301 for glycogen storage disease type Ia, the ESCAPE platform and BEAM-103 antibody, targeted lipid nanoparticle delivery research, financial results, cash runway commentary and participation in scientific and investor conferences. Coverage may also reference Beam’s equity stake in Orbital Therapeutics and the impact of Orbital’s acquisition by Bristol Myers Squibb, as disclosed by the company.
For readers tracking BEAM, this news feed provides ongoing insight into Beam’s clinical milestones, regulatory pathways, platform evolution and corporate transactions that shape the outlook for its precision genetic medicines pipeline.
Beam Therapeutics announced promising preclinical data on BEAM-102, a base editing approach targeting sickle cell disease (SCD). The data supports the conversion of sickle hemoglobin (HbS) to functional hemoglobin (HbG-Makassar). This research will be presented at the upcoming ASH Annual Meeting from December 11-14, 2021. Additionally, the company showcased novel lipid nanoparticle (LNP) screening technology that enhances the delivery of base editors to hematopoietic stem cells. This progress underscores Beam's commitment to innovative genetic treatments.
Beam Therapeutics (Nasdaq: BEAM) will showcase its innovative gene editing technologies at the Jefferies Gene Therapy/Editing Summit on October 27, 2021, at 4:00 p.m. ET. CEO John Evans will participate in a fireside chat, offering insights into the company's base editing platform, which allows precise genetic modifications without double-stranded breaks in DNA. This event reflects Beam's commitment to pioneering precision genetic medicines and its ongoing development of internal manufacturing capabilities. Interested parties can access the live webcast and its 60-day archive on Beam's investor website.
Beam Therapeutics has reported promising preclinical data demonstrating their liver-targeted base editing approach's ability to correct the R83C mutation associated with glycogen storage disease type Ia (GSDIa). These findings will be presented at the ESGCT 2021 Virtual Congress. The treatment, which uses a lipid nanoparticle to deliver an adenine base editor, led to normal glucose metabolism in mice models. Results showed an editing efficiency of approximately 60%, vital for restoring G6Pase activity and mitigating fasting hypoglycemia. Further preclinical studies are planned to advance this research.
Beam Therapeutics (Nasdaq: BEAM) announced preclinical data on multiplex edited allogeneic CAR T targeting CD5-positive hematologic malignancies. The findings, presented at the SITC Annual Meeting, highlight the potential of CD5 knockout to enhance CAR T-cell therapy efficacy against T-cell malignancies. Dr. Giuseppe Ciaramella emphasized that this innovative approach harnesses base editing for superior therapeutic benefits. Beam aims to pioneer precision genetic medicines and is developing internal manufacturing capabilities to support its advanced gene editing technologies.
Beam Therapeutics Inc. (Nasdaq: BEAM) will have its CEO, John Evans, participate in a fireside chat at the Chardan Virtual 5th Annual Genetic Medicines Conference on Oct. 5, 2021, at 8:00 a.m. ET. The event will be streamed live and accessible through the investor section of Beam's website, where it will remain archived for 60 days. Beam Therapeutics is focused on precision genetic medicines using innovative base editing technology, aimed at developing effective treatments while maintaining a commitment to cutting-edge science and patient care.
Beam Therapeutics (Nasdaq: BEAM) announced promising preclinical data at the 2021 International HBV Meeting regarding its cytosine base editors (CBEs) targeting hepatitis B virus (HBV). The study demonstrated significant reductions in viral markers, including HBsAg, utilizing multiplexing techniques. Results indicated a 30%-60% editing efficiency of cccDNA without reducing its levels, and a 20% enhanced efficacy when combined with standard antiviral treatment. Beam plans to advance its base editing approach to in vivo proof of concept models, highlighting its potential in treating chronic HBV infection.
Beam Therapeutics (Nasdaq: BEAM) announced new preclinical data on September 23, 2021, showcasing advancements in their lipid nanoparticle (LNP) formulations for in vivo liver editing. Key findings include up to 60% editing potency at 1.0 mg/kg in non-human primates (NHPs) and well-tolerated formulations at doses up to 1.5 mg/kg. The company also highlighted potential applications for delivering base editors beyond the liver to hematopoietic stem and progenitor cells (HSPCs). These developments may support future therapeutic applications for genetic diseases.
Beam Therapeutics (Nasdaq: BEAM) announced its participation in the 2021 Wells Fargo Virtual Healthcare Conference, where CEO John Evans will engage in a fireside chat on Sept. 10, 2021, at 9:20 a.m. ET. The event will be accessible via a live webcast on the company's investor website, with an archive available for 60 days post-event. Beam Therapeutics focuses on precision genetic medicines through its innovative base editing technology, which allows for precise single base changes in DNA without double-stranded breaks, aiming to provide long-term cures for serious diseases.
Beam Therapeutics reported significant progress in its base editing programs, with plans to submit its first IND for BEAM-101 in H2 2021. The company initiated IND-enabling studies for BEAM-201 targeting T-cell acute lymphoblastic leukemia. Financially, Beam's Q2 2021 net loss was $76.3 million, or $1.23 per share, compared to $34.2 million, or $0.69 per share, in Q2 2020. With a cash position of $615.3 million, the company is well-equipped to advance its innovative pipeline, including partnerships to expand therapeutic applications. Upcoming presentations scheduled for August and September 2021 will further highlight their advancements.
Beam Therapeutics (Nasdaq: BEAM) announced that its president and chief scientific officer, Giuseppe Ciaramella, Ph.D., will speak at the 2021 Wedbush PacGrow Healthcare Conference on Aug. 10, 2021, at 9:10 a.m. ET. The panel discussion, titled “So Let it Be (Re)Written - Updates in Gene Modulation,” will be available via a live webcast on the company's investor website and archived for 60 days. Beam Therapeutics specializes in precision genetic medicines through its proprietary base editing technology, allowing precise genomic alterations without DNA breaks.